Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: mirati.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $51.00 → $48.00 | Neutral → Buy | Citigroup |
| 8/9/2023 | $45.00 | Neutral → Buy | B. Riley Securities |
| 8/9/2023 | $45.00 | Overweight | Piper Sandler |
| 7/27/2023 | Sector Underperform | Scotiabank | |
| 5/25/2023 | Perform → Outperform | Oppenheimer | |
| 12/14/2022 | Hold | Needham | |
| 12/9/2022 | $121.00 → $53.00 | Buy → Neutral | Citigroup |
| 12/8/2022 | $110.00 → $59.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/8/2022 | $94.00 → $65.00 | Overweight → Neutral | JP Morgan |
| 12/8/2022 | $94.00 → $65.00 | Outperform → Market Perform | BMO Capital Markets |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy
15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
Fastest customizable press release news feed in the world
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh
Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor listed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancers SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasi
SAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. In the pooled analysis, adagrasib demonstrated durable efficacy with a median overall survival (OS) of 14.1 months and a 2-year OS rate of 31% in patients with previously treated KRASG12C-mutated NSCLC. Exploratory analyses suggested clinical benefit in patients with treated, stable central nervous
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 25,531 shares of Mirati's common stock, and in the aggregate, 15,089 restricted stock units ("RSUs"). The o
SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T. / 3:35 p.m. E.T. Ben Hickey, chief commercial officer, and Jamie Christensen, Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference. Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com. A replay of the webcast will be made available following the event. About Mirati Therapeutics, Inc.® Mirati Therapeutics, Inc. is a commerc
SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity. Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will assume the role of interim CFO. Ms. Stelzer will remain as a consultant to the company through October 2023. "On behalf of the Board and the Company, we thank Laurie for her leadership and the contributions made during her tenure," said Charles M. Baum, M.D., Ph.D., interim CEO, president and founder, Mirati Therapeutics. "It h
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented at the 2023 World Conference on Lung Cancer during the press conference on September 10th 10:35 a.m. – 10:40 a.m. SGT / September 9th 7:35 p.m. – 7:40 p.m. PT and as a mini-oral presentation in the "Targeted Therapy: KRAS and Beyond" session occurring on September 10th at 4:22 p.m. SGT / 1:22 a
SAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the closing of its previously announced underwritten public offering of 11,288,336 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares
Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously
B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00
Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00
Scotiabank initiated coverage of Mirati Therapeutics with a rating of Sector Underperform
Oppenheimer upgraded Mirati Therapeutics from Perform to Outperform
Needham initiated coverage of Mirati Therapeutics with a rating of Hold
Citigroup downgraded Mirati Therapeutics from Buy to Neutral and set a new price target of $53.00 from $121.00 previously
BMO Capital Markets downgraded Mirati Therapeutics from Outperform to Market Perform and set a new price target of $59.00 from $110.00 previously
JP Morgan downgraded Mirati Therapeutics from Overweight to Neutral and set a new price target of $65.00 from $94.00 previously
BMO Capital Markets downgraded Mirati Therapeutics from Outperform to Market Perform and set a new price target of $65.00 from $94.00 previously
This live feed shows all institutional transactions in real time.
SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)
SC 13D/A - Mirati Therapeutics, Inc. (0001576263) (Subject)
Live Leadership Updates
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer." Dr. Gallagher has over 30 years of strategic, commercial, business development and drug dev
Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pr
- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine. Prior to Medikine, he was Executive Vice President a
SAN DIEGO, May 16, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek. David commented, "We are excited to have Laurie join Mirati. She brings extensive finance expertise and strategic insights, which will be invaluable as we continue to deliver on our ambitious goals, including working toward our first potential launch in the U.S. t
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also join the Company's Board of Directors. Charles M. Baum, M.D., Ph.D. will continue to lead the research and development (R&D) organization as president, founder and head of R&D. Dr. Baum will remain on the Company's Board of Directors. Mr. Meek has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology, includ
Live finance-specific insights
Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum, M.D., Ph.D., President and Founder, to assume role of interim CEO during search for permanent CEO Company will announce financial results for the second quarter 2023 along with recent corporate updates during a conference call at 5:30 p.m. ET / 2:30 p.m. PT SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASD
SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 6674271. A replay of the call will be available approximately 2 hours after
SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In add
SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 8109078. A replay of the call will be available approximately 2 hours after the ev
SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates. "2022 was a momentous year for Mirati, culminating in the approval and launch of KRAZATI™ as a treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRASG12C mutation. We believe this is the first of several potentially best-in-class products on the horizon for Mirati," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In addition to the approval of KRAZATITM, in 2022 we advanced MRTX1719 an
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 2312901. A replay of the call will be available approximately 2 ho
SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates. "In the third quarter, we made notable advancements within our targeted oncology portfolio, while executing on strategic priorities to position Mirati for continued success," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "The fourth quarter includes several exciting milestones for Mirati, including our anticipated Prescription Drug User Fee Act (PDUFA) date for adagrasib, which we are prepared to launch upon approval, the release of topline interim data fo
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on November 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 866-409-1555, confirmation code: 8269398. A replay of the call will be available approximately 2 hour
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates. "Mirati continues to advance the development of a broad portfolio of targeted oncology medicines," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "We are progressing toward the potential launch of adagrasib for patients with previously treated non-small cell lung cancer harboring a KRASG12C mutation in the U.S. this year. In addition, we have submitted a Marketing Authorization Application to the European Medicines Agency, bringing us one step closer to ex
SAN DIEGO, July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 3, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 313-209-4906 or international +1 877-502-9276, confirmation code: 1791105. A replay of the call will be available approximately 2 hours a